版本:
中国

BRIEF-Arbutus licenses LNP delivery technology to Alexion

March 16 Arbutus Biopharma Corp

* Arbutus licenses LNP delivery technology to Alexion for use in single messenger RNA product candidate

* Arbutus Biopharma Corp says under terms of license agreement, Alexion will pay Arbutus $7.5 million upfront

* Arbutus Biopharma Corp says Alexion will also make payments of up to $75 million for achievement of development, regulatory, and commercial milestones

* Arbutus Biopharma Corp says transaction enables Alexion to address delivery for therapeutic application of messenger RNA

* Arbutus Biopharma Corp says transaction also enables Alexion to rapidly enter clinical development with its MRNA product candidate

* Arbutus Biopharma - licensed to Alexion Pharma its proprietary lipid nanoparticle technology for exclusive use in one of Alexion's rare disease programs Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐